What's Happening?
TruDiagnostic has been awarded a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to advance its W-Function Epigenomic Roadmap. This innovative model aims to map dynamic changes in DNA methylation, providing insights into disease onset, progression, and treatment response. By utilizing the largest longitudinal methylation dataset, TruDiagnostic seeks to improve predictive accuracy and identify new therapeutic targets. The initial focus will be on cardiovascular disease, type 2 diabetes, and mortality risk, with potential applications across various chronic conditions.
Why It's Important?
The development of the W-Function Epigenomic Roadmap represents a shift towards more dynamic and personalized health diagnostics. By focusing on epigenetic changes, this technology could enhance early disease detection, guide personalized treatment plans, and accelerate drug discovery. The grant from NIH underscores the potential impact of this research on public health, offering a proactive approach to managing chronic diseases and improving patient outcomes. Healthcare providers and patients could benefit from more accurate health forecasts and targeted interventions.
What's Next?
TruDiagnostic will continue to develop and validate the W-Function Epigenomic Roadmap, with plans to expand its applications to other chronic diseases. The success of this project could lead to broader adoption of epigenetic diagnostics in clinical practice, transforming how diseases are predicted and managed. As the research progresses, it may attract further investment and collaboration opportunities, driving innovation in the field of precision health.
